Posts in tag

biologics


Pharmacists’ authority to use their expertise to substitute one medicine for another should also apply to biological medicines, says FIP The International Pharmaceutical Federation has published a revised Statement of …

In the latest in our series based on 2017 UTS Pharmacy Barometer results, John Montgomery looks at how pharmacists view the riding tide of biosimilar medicines  There’s little doubt biosimilar …

The ACTU has attacked the government over the revived TPP, claiming it would drive up drug prices ACTU president Ged Kearney says that the Trans Pacific Partnership, which is set …

Time for costly medicine monopolies to go from TPP trade talks Belinda Townsend, Australian National University; Deborah Gleeson, La Trobe University; Hazel Moir, Australian National University; Joel Lexchin, University of …

Guild Learning and Development is partnering with AbbVie Pty Ltd in an online course titled “Understanding biologic medicines” AbbVie’s General Manager Kirsten O’Doherty says the course plays an important role …

Minister confirms a range of initiatives to boost pharmacy’s primary care role The Federal government is moving to give certainty to community pharmacy over location rules, Health Minister Greg Hunt …

The asthma medicines market is set to grow with incoming biologics and climbing disease rates, say market researchers The asthma therapeutics market in the Asia-Pacific region is expected to grow from …

While they present a cost-saving opportunity, safety data on biosimilars is still limited, warns IBD specialist There is an absence of data on adverse reactions or potential development of anti-drug …

The way a biosimilar is named may affect whether a pharmacist is willing to substitute it for a brand name biologic, a new study has found. The study, published in …

Pfizer has unveiled the final phase of its $21 million investment which it says will establish Adelaide as a global manufacturing hub for a medicine commonly used to treat complications …

The inclusion of the first monoclonal antibody biosimilar on the PBS will deliver immediate savings to the Federal Government; however the full potential of this and other biosimilar medicines relies …

Pfizer today confirmed that the first mAb biosimilar, Inflectra (infliximab), will be added to the PBS on 1 December 2015 for the treatment of eight inflammatory conditions.